# Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma

> **NCT00113529** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 42 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Gefitinib + Sunitinib

## Key facts

- **NCT ID:** NCT00113529
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2007-09
- **Final completion:** 2008-10
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2011-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00113529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00113529, "Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00113529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*